CST, 96641S, TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying TNFRSF13B. Validated for WB,IP,IF,F,F. Available in 2 sizes. Highly specific and rigorously validated in-house, TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody (CST #96641) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:100 Immunofluorescence (Immunocytochemistry): 1:800 - 1:3200 Flow Cytometry (Fixed/Permeabilized): 1:50 - 1:200 Flow Cytometry (Live): 1:50 - 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized), Flow Cytometry (Live) Specificity / Sensitivity TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody recognizes endogenous levels of total TACI/TNFRSF13B/CD267 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human TACI/TNFRSF13B/CD267 protein. Background Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) and cluster of differentiation 267 (CD267), is a single-pass type III membrane receptor that is highly expressed on the surface of mature innate-like B cells, such as marginal zone and B-1 B cells in mice, and memory B cells in humans (1-3). TACI/TNFRSF13B/CD267 is also expressed on the surface of activated T cells (4), while monocytes and dendritic cells express lower levels of TACI/TNFRSF13B/CD267 primarily intracellularly (5,6). TACI/TNFRSF13B/CD267 is the receptor for soluble ligands BAFF/TNFSF13B and APRIL/TNFSF13 (7,8). Upon ligation, TACI/TNFRSF13B/CD267 recruits tumor necrosis factor receptor-associated factor (TRAF) family members and calcium signal-modulating cyclophilin ligand (CAMLG) in order to activate NFAT, NF-κB, and AP-1 transcriptional programs (9-11). TACI/TNFRSF13B/CD267 is necessary for T cell-independent type II and type I responses (1,12), negative regulation of B cell and T follicular helper cell numbers (13,14), and promotion of class switch recombination in B cells (15). Mutations and aberrant regulation of TACI/TNFRSF13B/CD267 has been associated with cancer, autoimmune diseases, and immunodeficiency disorders (16-18). Multiple isoforms produced by alternative splicing have been identified. Alternate Names CD267; CVID; CVID2; FLJ39942; IGAD2; MGC133214; MGC39952; RYZN; TACI; TNF receptor superfamily member 13B; TNFRSF13B; TNFRSF14B; TR13B; Transmembrane activator and CAML interactor; tumor necrosis factor receptor 13B; Tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor superfamily, member 13B Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 30-40 Source/Isotype: Rabbit IgG